New perspectives in the studies on endocannabinoid and cannabis: Abnormal behaviors associate with CB1 cannabinoid receptor and development of therapeutic application

Michihiro Fujiwara, Nobuaki Egashira

Research output: Contribution to journalShort survey

60 Citations (Scopus)

Abstract

Δ9-Tetrahydrocannabinol (Δ9-THC), the major psychoactive component of marijuana, induces catalepsy-like immobilization and impairment of spatial memory in rats. Δ9-THC also induces aggressive behavior in isolated housing stress. These abnormal behaviors could be counteracted by SR141716A, a CB1 cannabinoid receptor antagonist. Also Δ9-THC inhibited release of glutamate in the dorsal hippocampus, but this inhibition could be antagonized by SR141716A in an in vivo microdialysis study. Moreover, NMDA and AMPA-type glutamate receptor enhancers improved the Δ9-THC-induced impairment of spatial memory. On the other hand, Δ9-THC markedly inhibited the neurodegeneration in experimental allergic encephalomyelitis (EAE), an animal model of multiple sclerosis and reduced the elevated glutamate level of cerebrospinal fluid induced by EAE. These therapeutic effects on EAE were reversed by SR141716A. Taken together, our results demonstrate that the inhibition of glutamate release via activation of the CB1-cannabinoid receptor is one mechanism involved in Δ9-THC-induced impairment of spatial memory, and the therapeutic effect of Δ9-THC on EAE, and a Δ9-THC analog might provide an effective treatment for psychosis and neurodegenerative diseases.

Original languageEnglish
Pages (from-to)362-366
Number of pages5
JournalJournal of Pharmacological Sciences
Volume96
Issue number4
DOIs
Publication statusPublished - Dec 1 2004
Externally publishedYes

Fingerprint

Cannabinoid Receptor CB1
Endocannabinoids
Dronabinol
Cannabis
rimonabant
Autoimmune Experimental Encephalomyelitis
Glutamic Acid
Therapeutic Uses
Therapeutics
Cannabinoid Receptor Antagonists
Catalepsy
AMPA Receptors
Microdialysis
Glutamate Receptors
N-Methylaspartate
Immobilization
Neurodegenerative Diseases
Psychotic Disorders
Multiple Sclerosis
Cerebrospinal Fluid

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology

Cite this

@article{279a71bd84ed498cbecee473c34cb6d1,
title = "New perspectives in the studies on endocannabinoid and cannabis: Abnormal behaviors associate with CB1 cannabinoid receptor and development of therapeutic application",
abstract = "Δ9-Tetrahydrocannabinol (Δ9-THC), the major psychoactive component of marijuana, induces catalepsy-like immobilization and impairment of spatial memory in rats. Δ9-THC also induces aggressive behavior in isolated housing stress. These abnormal behaviors could be counteracted by SR141716A, a CB1 cannabinoid receptor antagonist. Also Δ9-THC inhibited release of glutamate in the dorsal hippocampus, but this inhibition could be antagonized by SR141716A in an in vivo microdialysis study. Moreover, NMDA and AMPA-type glutamate receptor enhancers improved the Δ9-THC-induced impairment of spatial memory. On the other hand, Δ9-THC markedly inhibited the neurodegeneration in experimental allergic encephalomyelitis (EAE), an animal model of multiple sclerosis and reduced the elevated glutamate level of cerebrospinal fluid induced by EAE. These therapeutic effects on EAE were reversed by SR141716A. Taken together, our results demonstrate that the inhibition of glutamate release via activation of the CB1-cannabinoid receptor is one mechanism involved in Δ9-THC-induced impairment of spatial memory, and the therapeutic effect of Δ9-THC on EAE, and a Δ9-THC analog might provide an effective treatment for psychosis and neurodegenerative diseases.",
author = "Michihiro Fujiwara and Nobuaki Egashira",
year = "2004",
month = "12",
day = "1",
doi = "10.1254/jphs.FMJ04003X2",
language = "English",
volume = "96",
pages = "362--366",
journal = "Journal of Pharmacological Sciences",
issn = "1347-8613",
publisher = "Japanese Pharmacological Society",
number = "4",

}

TY - JOUR

T1 - New perspectives in the studies on endocannabinoid and cannabis

T2 - Abnormal behaviors associate with CB1 cannabinoid receptor and development of therapeutic application

AU - Fujiwara, Michihiro

AU - Egashira, Nobuaki

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Δ9-Tetrahydrocannabinol (Δ9-THC), the major psychoactive component of marijuana, induces catalepsy-like immobilization and impairment of spatial memory in rats. Δ9-THC also induces aggressive behavior in isolated housing stress. These abnormal behaviors could be counteracted by SR141716A, a CB1 cannabinoid receptor antagonist. Also Δ9-THC inhibited release of glutamate in the dorsal hippocampus, but this inhibition could be antagonized by SR141716A in an in vivo microdialysis study. Moreover, NMDA and AMPA-type glutamate receptor enhancers improved the Δ9-THC-induced impairment of spatial memory. On the other hand, Δ9-THC markedly inhibited the neurodegeneration in experimental allergic encephalomyelitis (EAE), an animal model of multiple sclerosis and reduced the elevated glutamate level of cerebrospinal fluid induced by EAE. These therapeutic effects on EAE were reversed by SR141716A. Taken together, our results demonstrate that the inhibition of glutamate release via activation of the CB1-cannabinoid receptor is one mechanism involved in Δ9-THC-induced impairment of spatial memory, and the therapeutic effect of Δ9-THC on EAE, and a Δ9-THC analog might provide an effective treatment for psychosis and neurodegenerative diseases.

AB - Δ9-Tetrahydrocannabinol (Δ9-THC), the major psychoactive component of marijuana, induces catalepsy-like immobilization and impairment of spatial memory in rats. Δ9-THC also induces aggressive behavior in isolated housing stress. These abnormal behaviors could be counteracted by SR141716A, a CB1 cannabinoid receptor antagonist. Also Δ9-THC inhibited release of glutamate in the dorsal hippocampus, but this inhibition could be antagonized by SR141716A in an in vivo microdialysis study. Moreover, NMDA and AMPA-type glutamate receptor enhancers improved the Δ9-THC-induced impairment of spatial memory. On the other hand, Δ9-THC markedly inhibited the neurodegeneration in experimental allergic encephalomyelitis (EAE), an animal model of multiple sclerosis and reduced the elevated glutamate level of cerebrospinal fluid induced by EAE. These therapeutic effects on EAE were reversed by SR141716A. Taken together, our results demonstrate that the inhibition of glutamate release via activation of the CB1-cannabinoid receptor is one mechanism involved in Δ9-THC-induced impairment of spatial memory, and the therapeutic effect of Δ9-THC on EAE, and a Δ9-THC analog might provide an effective treatment for psychosis and neurodegenerative diseases.

UR - http://www.scopus.com/inward/record.url?scp=12444273710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12444273710&partnerID=8YFLogxK

U2 - 10.1254/jphs.FMJ04003X2

DO - 10.1254/jphs.FMJ04003X2

M3 - Short survey

C2 - 15599103

AN - SCOPUS:12444273710

VL - 96

SP - 362

EP - 366

JO - Journal of Pharmacological Sciences

JF - Journal of Pharmacological Sciences

SN - 1347-8613

IS - 4

ER -